Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B

Table 1 Characteristics of patients with drug-resistant chronic hepatitis B stratified by hepatocellular carcinoma status n (%)

Variables	Patients with HCC (n = 57)	Patients without HCC (n = 375)	P-value
Gender (male)	42 (73.7)	267 (71.2)	0.755
Age (mean, yr)	57.44 ± 8.35	47.03 ± 12.25	< 0.001
Presence of cirrhosis	42 (73.7)	85 (22.7)	< 0.001
HBeAg positivity	36 (63.2)	314 (83.7)	0.003
Seroconversion of HBeAg	3 (5.3)	78 (20.8)	0.022
Initial HBV DNA (< 2000 IU)	2 (3.5)	27 (7.2)	0.61
Initial HBV DNA (> 20000 IU)	46 (80.7)	314 (83.7)	0.162
Complete virologic response	11 (19.3)	135 (36)	0.02
Partial virologic response	31 (54.4)	271 (72.3)	0.012
Platelet count (103/mm3) (median, range)	103 (35-380)	164.5 (34-330)	< 0.001
AST U/L (median, range)	79.5 (22-707)	63 (14-1494)	0.126
ALT U/L (median, range)	86.5 (11-590)	82 (9-2280)	0.770
AFP IU/mL (median, range)	7.58 (1.54-1890)	2.8 (0.65-980)	< 0.001
Child-Pugh score	5.51 ± 0.85	5.12 ± 0.71	0.002
Viral mutation
rtM204I	25 (43.9)	93 (24.8)	0.004
rtM204I/rtL180M	4 (7)	50 (13.3)	0.098
rtM204V/rtL180M	14 (24.6)	111 (29.6)	0.492
rtM204V + I/rtL180M	3 (5.3)	36 (9.6)	0.451
rtA181T	3 (5.3)	22 (5.9)	1
rtA181T/V	1 (1.8)	1 (0.26)	0.224
Duration of antiviral treatment (mo)	24.31 ± 15.28	31.43 ± 19.43	0.004

HCC: Hepatocellular carcinoma; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; AST: Aspartate aminotransferase; HBV: Hepatitis B virus.